Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn study sought to boost RA remission with education and team care

NCT ID NCT02720874

Disease control Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study was designed to test whether a combination of an educational booklet, team-based care from a rheumatologist, physical therapist, and psychologist, plus nurse-led phone calls and home symptom tracking, could help more Hispanic adults with rheumatoid arthritis achieve remission. The trial was withdrawn before any participants were enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (educational booklet, multidisciplinary care, nurse calls)
What this could lead to
If successful, this approach could improve remission rates in underserved populations with rheumatoid arthritis.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. The intervention is complex and may not be feasible in other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jan 2025

An estimate. Start dates often move.

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Reside in Greater Los Angeles area and receive rheumatologic care at the adult rheumatology clinic at Harbor-UCLA Medical Center in Torrance, California * Fulfill the 2010 American College of Rheumatology revised diagnostic criteria for RA * Have at least moderate disease activity as indicated by a Clinical Disease Activity Index (CDAI) score \>10 and Routine Assessment Patient Index Data (RAPID3) score \>2 * Be able and willing to provide written informed consent and to adhere to the study visit schedule and other protocol * Availability of a touch-tone landline or mobile telephone * Of self-identified Hispanic/Latino descent Exclusion Criteria: * Known irreversible articular damage, including subluxations, arthrodesis, fusion, or prosthesis * Functional class IV as defined by the American College of Rheumatology Classification of Functional Status in rheumatoid arthritis * Overlapping autoimmune or mixed connective tissue syndromes * Serious medical conditions, including: chronic infection, advanced or decompensated heart failure, higher than class II chronic kidney disease, cancer (unless in remission for period of 5 years or more), or any uncontrolled medical condition that is deemed by the investigators to interfere with the study protocol * At risk for suicide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis rheumatoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis rheumatoid

Contacts and locations

Locations

  • The Lundquist Institute at Harbor-UCLA Medical Center

    Torrance, California, 90502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.